Changes in immune function in patients receiving natural leukocyte interferon
Highly purified human lymphoblastoid interferon derived from virus-stimulated Namalwa cells was administered daily by 6-h i.v. infusion or i.m. injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received escalating doses of 0.1-50 X 10(6...
Gespeichert in:
| Veröffentlicht in: | Journal of biological response modifiers 1983, Vol.2 (5), p.418-427 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 427 |
|---|---|
| container_issue | 5 |
| container_start_page | 418 |
| container_title | Journal of biological response modifiers |
| container_volume | 2 |
| creator | Maluish, A E Ortaldo, J R Sherwin, S A Oldham, R K Herberman, R B |
| description | Highly purified human lymphoblastoid interferon derived from virus-stimulated Namalwa cells was administered daily by 6-h i.v. infusion or i.m. injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received escalating doses of 0.1-50 X 10(6) U for up to 5 weeks. Extensive monitoring for changes in various immune functions revealed no sustained elevation in natural killer cell activity, elevated monocyte-mediated antitumor cytostatic activity in approximately 30% of the patients, and depressed lymphoproliferative responses to mitogens and mixed leukocyte culture. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80771971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80771971</sourcerecordid><originalsourceid>FETCH-LOGICAL-p206t-12dfbd1e009582bd79bd01aaf1385df05ecb36bd6524f19df3a301852246e08a3</originalsourceid><addsrcrecordid>eNotz8tKxDAYBeAslHEcfQQhK3eFXJo0XUrxBiNudF2S5s8YbdOaizBv74hdHTh8HDhnaEsaziopFLlAlyl9EiI4o2KDNlLWNa_lFr10HzocIGEfsJ-mEgC7Eobs5_BXLTp7CDnhCAP4Hx8OOOhcoh7xCOVrHo4ZTi5DdBDncIXOnR4TXK-5Q-8P92_dU7V_fXzu7vbVwojMFWXWGUuBkFYoZmzTGkuo1o5yJawjAgbDpbFSsNrR1jquOaFKMFZLIErzHbr9313i_F0g5X7yaYBx1AHmknpFmoa2DT3BmxUWM4Htl-gnHY_9-p__Ar7WVt4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80771971</pqid></control><display><type>article</type><title>Changes in immune function in patients receiving natural leukocyte interferon</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Maluish, A E ; Ortaldo, J R ; Sherwin, S A ; Oldham, R K ; Herberman, R B</creator><creatorcontrib>Maluish, A E ; Ortaldo, J R ; Sherwin, S A ; Oldham, R K ; Herberman, R B</creatorcontrib><description>Highly purified human lymphoblastoid interferon derived from virus-stimulated Namalwa cells was administered daily by 6-h i.v. infusion or i.m. injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received escalating doses of 0.1-50 X 10(6) U for up to 5 weeks. Extensive monitoring for changes in various immune functions revealed no sustained elevation in natural killer cell activity, elevated monocyte-mediated antitumor cytostatic activity in approximately 30% of the patients, and depressed lymphoproliferative responses to mitogens and mixed leukocyte culture.</description><identifier>ISSN: 0732-6580</identifier><identifier>PMID: 6644346</identifier><language>eng</language><publisher>United States</publisher><subject>Cytotoxicity, Immunologic ; Humans ; Infusions, Parenteral ; Injections, Intramuscular ; Interferon Type I - immunology ; Interferon Type I - therapeutic use ; Killer Cells, Natural - immunology ; Monocytes - immunology ; Neoplasms - immunology ; Neoplasms - therapy</subject><ispartof>Journal of biological response modifiers, 1983, Vol.2 (5), p.418-427</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,4025</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6644346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maluish, A E</creatorcontrib><creatorcontrib>Ortaldo, J R</creatorcontrib><creatorcontrib>Sherwin, S A</creatorcontrib><creatorcontrib>Oldham, R K</creatorcontrib><creatorcontrib>Herberman, R B</creatorcontrib><title>Changes in immune function in patients receiving natural leukocyte interferon</title><title>Journal of biological response modifiers</title><addtitle>J Biol Response Mod</addtitle><description>Highly purified human lymphoblastoid interferon derived from virus-stimulated Namalwa cells was administered daily by 6-h i.v. infusion or i.m. injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received escalating doses of 0.1-50 X 10(6) U for up to 5 weeks. Extensive monitoring for changes in various immune functions revealed no sustained elevation in natural killer cell activity, elevated monocyte-mediated antitumor cytostatic activity in approximately 30% of the patients, and depressed lymphoproliferative responses to mitogens and mixed leukocyte culture.</description><subject>Cytotoxicity, Immunologic</subject><subject>Humans</subject><subject>Infusions, Parenteral</subject><subject>Injections, Intramuscular</subject><subject>Interferon Type I - immunology</subject><subject>Interferon Type I - therapeutic use</subject><subject>Killer Cells, Natural - immunology</subject><subject>Monocytes - immunology</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><issn>0732-6580</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotz8tKxDAYBeAslHEcfQQhK3eFXJo0XUrxBiNudF2S5s8YbdOaizBv74hdHTh8HDhnaEsaziopFLlAlyl9EiI4o2KDNlLWNa_lFr10HzocIGEfsJ-mEgC7Eobs5_BXLTp7CDnhCAP4Hx8OOOhcoh7xCOVrHo4ZTi5DdBDncIXOnR4TXK-5Q-8P92_dU7V_fXzu7vbVwojMFWXWGUuBkFYoZmzTGkuo1o5yJawjAgbDpbFSsNrR1jquOaFKMFZLIErzHbr9313i_F0g5X7yaYBx1AHmknpFmoa2DT3BmxUWM4Htl-gnHY_9-p__Ar7WVt4</recordid><startdate>1983</startdate><enddate>1983</enddate><creator>Maluish, A E</creator><creator>Ortaldo, J R</creator><creator>Sherwin, S A</creator><creator>Oldham, R K</creator><creator>Herberman, R B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1983</creationdate><title>Changes in immune function in patients receiving natural leukocyte interferon</title><author>Maluish, A E ; Ortaldo, J R ; Sherwin, S A ; Oldham, R K ; Herberman, R B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p206t-12dfbd1e009582bd79bd01aaf1385df05ecb36bd6524f19df3a301852246e08a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Cytotoxicity, Immunologic</topic><topic>Humans</topic><topic>Infusions, Parenteral</topic><topic>Injections, Intramuscular</topic><topic>Interferon Type I - immunology</topic><topic>Interferon Type I - therapeutic use</topic><topic>Killer Cells, Natural - immunology</topic><topic>Monocytes - immunology</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Maluish, A E</creatorcontrib><creatorcontrib>Ortaldo, J R</creatorcontrib><creatorcontrib>Sherwin, S A</creatorcontrib><creatorcontrib>Oldham, R K</creatorcontrib><creatorcontrib>Herberman, R B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biological response modifiers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maluish, A E</au><au>Ortaldo, J R</au><au>Sherwin, S A</au><au>Oldham, R K</au><au>Herberman, R B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in immune function in patients receiving natural leukocyte interferon</atitle><jtitle>Journal of biological response modifiers</jtitle><addtitle>J Biol Response Mod</addtitle><date>1983</date><risdate>1983</risdate><volume>2</volume><issue>5</issue><spage>418</spage><epage>427</epage><pages>418-427</pages><issn>0732-6580</issn><abstract>Highly purified human lymphoblastoid interferon derived from virus-stimulated Namalwa cells was administered daily by 6-h i.v. infusion or i.m. injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received escalating doses of 0.1-50 X 10(6) U for up to 5 weeks. Extensive monitoring for changes in various immune functions revealed no sustained elevation in natural killer cell activity, elevated monocyte-mediated antitumor cytostatic activity in approximately 30% of the patients, and depressed lymphoproliferative responses to mitogens and mixed leukocyte culture.</abstract><cop>United States</cop><pmid>6644346</pmid><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-6580 |
| ispartof | Journal of biological response modifiers, 1983, Vol.2 (5), p.418-427 |
| issn | 0732-6580 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80771971 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Cytotoxicity, Immunologic Humans Infusions, Parenteral Injections, Intramuscular Interferon Type I - immunology Interferon Type I - therapeutic use Killer Cells, Natural - immunology Monocytes - immunology Neoplasms - immunology Neoplasms - therapy |
| title | Changes in immune function in patients receiving natural leukocyte interferon |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T14%3A01%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20immune%20function%20in%20patients%20receiving%20natural%20leukocyte%20interferon&rft.jtitle=Journal%20of%20biological%20response%20modifiers&rft.au=Maluish,%20A%20E&rft.date=1983&rft.volume=2&rft.issue=5&rft.spage=418&rft.epage=427&rft.pages=418-427&rft.issn=0732-6580&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E80771971%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80771971&rft_id=info:pmid/6644346&rfr_iscdi=true |